Geoscience Center of the University of Göttingen, Dept. Applied Geology, Goldschmidtstr. 3, 37077 Göttingen, Germany.
Water Res. 2013 Nov 1;47(17):6650-9. doi: 10.1016/j.watres.2013.08.034. Epub 2013 Sep 10.
The substantial transformation of the angiotensin II receptor antagonist valsartan to the transformation product 2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (referred to as valsartan acid) during the activated sludge process was demonstrated in the literature and confirmed in the here presented study. However, there was a severe lack of knowledge regarding the occurrence and fate of this compound in surface water and its behavior during drinking water treatment. In this work a comparative study on the occurrence and persistency of valsartan acid, three frequently used β-blockers (metoprolol, atenolol, and sotalol), atenolol acid (one significant transformation product of atenolol and metoprolol), and the two widely distributed persistent anthropogenic wastewater indicators carbamazepine and acesulfame in raw sewage, treated wastewater, surface water, groundwater, and tap water is presented. Median concentrations of valsartan acid in the analyzed matrices were 101, 1,310, 69, <1.0, and 65 ng L(-1), respectively. Treated effluents from wastewater treatment plants were confirmed as significant source. Regarding concentration levels of pharmaceutical residues in surface waters valsartan acid was found just as relevant as the analyzed β-blockers and the anticonvulsant carbamazepine. Regarding its persistency in surface waters it was comparable to carbamazepine and acesulfame. Furthermore, removal of valsartan acid during bank filtration was poor, which demonstrated the relevance of this compound for drinking water suppliers. Regarding drinking water treatment (Muelheim Process) the compound was resistant to ozonation but effectively eliminated (≥90%) by subsequent activated carbon filtration. However, without applying activated carbon filtration the compound may enter the drinking water distribution system as it was demonstrated for Berlin tap water.
在活性污泥过程中,血管紧张素 II 受体拮抗剂缬沙坦会实质性地转化为转化产物 2'-(2H-四唑-5-基)-[1,1'-联苯]-4-羧酸(简称缬沙坦酸),这在文献中已有证明,并在本研究中得到了证实。然而,人们对这种化合物在地表水环境中的存在和归宿及其在饮用水处理过程中的行为知之甚少。在这项工作中,对缬沙坦酸、三种常用的β-受体阻滞剂(美托洛尔、阿替洛尔和索他洛尔)、阿替洛尔酸(阿替洛尔和美托洛尔的一个重要转化产物)、以及卡马西平和乙酰磺胺在原污水、处理后的污水、地表水、地下水和自来水中的出现和持久性进行了比较研究。在分析的基质中,缬沙坦酸的中位数浓度分别为 101、1310、69、<1.0 和 65ng/L。从废水处理厂的处理废水中可以确认其为重要的来源。就地表水中的药物残留浓度而言,缬沙坦酸与所分析的β-受体阻滞剂和抗惊厥药卡马西平一样重要。就其在地表水中的持久性而言,它与卡马西平和乙酰磺胺相当。此外,在河岸过滤过程中,缬沙坦酸的去除效果很差,这表明该化合物对饮用水供应商具有重要意义。就饮用水处理(穆尔海姆工艺)而言,该化合物对臭氧处理具有抗性,但通过随后的活性炭过滤可以有效地去除(≥90%)。然而,如果不应用活性炭过滤,该化合物可能会进入饮用水分配系统,正如柏林自来水所证明的那样。